After being fired, I became the light of medicine

Chapter 107 Half-year Financial Report & Inventory of Profits! (Subscription Request)
As usual, Zhang Yang withdrew the drug reward before exiting the simulator.

but,

Zhang Yang was powerless to change the final outcome, just like the final text summary of the simulator.
The key to kidney disease is early detection and early treatment. Once it reaches the stage of uremia, no one can reverse it.

Fortunately, although this reward is only a temporary emergency alternative to dialysis, it can provide a better quality of life for some dialysis patients.

In the following days, Zhang Yang began to study this "Kidney Toxin Clearing Dialysis Replacement Injection".
He still planned to do the same as before, first thoroughly understand the composition and mechanism of action of this drug, and then hand it over to the R&D center for secondary development, and finally achieve complete results and put it on the market.

Although this is troublesome, the drug has gone through a complete research and development process, which is much more reasonable than taking it out directly by yourself.

Moreover, he has noticed that not only has his own understanding of drugs greatly improved in the process of learning, but the R&D members of the entire R&D center team have also seen their capabilities rapidly improved due to their participation in the development of these excellent semi-finished drugs.

In that case, why not do it?

Just as Zhang Yang was fully immersed in the study of "Kidney Toxin Clearing Injection", on July 7, Ren Xiaomin walked into the office with a thick document and a smile on his face.

"Zhang Yang, guess what I'm holding in my hand?"

Zhang Yang put away the animal experiment data on the table, smiled and shook his head.

"Brother Ren, I can't guess, but judging by your expression it must be a good thing."

"Haha, yes, it's good news!"

Ren Xiaomin laughed.

As Qingshan Pharmaceutical grows stronger, the division of labor between him and Zhang Yang becomes clearer.

Zhang Yang is mainly responsible for drug research and development, that is, the affairs of the R&D center, as well as major decisions of the company, such as signing an agency contract with Novartis.

He is mainly responsible for internal management of the company, coordination of resources, human resource recruitment and other internal affairs. He can be said to be the one who is in charge of both internal affairs and external affairs.

Zhang Yang was naturally very confident in Ren Xiaomin. Ren's more than ten years of experience in Beifeng Pharmaceutical was enough to show that he was an upright person with no intrigue. Having him manage the company would ensure that there would be no chaos, and it would also save him a lot of energy.

"Okay, I won't play dumb. This is because all the major hospitals and agents have settled their drug payments for the first half of this year, and the medical insurance has added an order for 'Acofenprofovir'.

Look at how much money we have made in the past six months!"

Oh?
Zhang Yang was also quite curious, and hurriedly took the semi-annual financial report from Ren Xiaomin. After taking a few glances at it, he was immediately surprised.

Currently, Qingshan Pharmaceutical has a total of three drugs for sale.

The first one is "Qingshan Avaqubopa".

With the comprehensive promotion and application of "Qingshan Afa" in Huaxia Hospital over the past two years, "Qingshan Afa" has become the main first-line treatment drug for "thrombocytopenia" in China!
It is widely used in hematology, hepatology and oncology departments.

In the first half of the year alone, Qingshan Avatrombopag shipped more than 100 million boxes, with sales reaching 4.8 million yuan, successfully taking over AkaRx's previous market share.

of course,

Since the prices of first-generation platelet therapeutic drugs such as Eltrombopag have been reduced to be much cheaper than Qingshan Ava, many patients still choose to continue taking Eltrombopag.

There are also some patients who are not unable to afford the medicine, but are afraid of taking the best "Qingshan Afa" directly, and in the end, if drug resistance occurs, there will be no alternative medicine.

But no matter what, "Qingshan Afa" has become the best drug for treating "thrombocytopenia" and firmly occupies the largest share of the top market.

As Tsingshan Pharmaceutical quickly entered major tertiary hospitals, AkaRx also completely changed its sales strategy. They no longer pursued a price war with Tsingshan Pharmaceutical, but turned to private hospitals in China, harvesting the country's middle class in the name of "imported drugs."

Zhang Yang is very satisfied with the sales situation. After all, "Qingshan Afa" is a medicine that needs to be taken for a long time, and as time goes by, the market penetration rate of "Qingshan Afa" will increase in the next ten years.

He turned his eyes to the second drug - "ITG human myelopoietin".

In the first half of the year, the domestic sales volume of "ITG Injection" reached 100 million units, each unit costing RMB 2800, and the total domestic sales amount reached RMB 28 billion!

Assuming that one patient requires 10 injections, patients were cured last year alone.

There are 150 million patients with aplastic anemia in China. Perhaps because their symptoms are not serious, or perhaps because there is not enough money for treatment at the moment, most of them have not taken any action.

But Zhang Yang was already very satisfied with the data.

It can be predicted that at least in the next five years, more patients with aplastic anemia will continue to receive treatment, and "ITG human myelogenin" will at least bring Qingshan Pharmaceutical more than 10 billion yuan in sales.

In addition to domestic sales data, sales to Southeast Asia represented by Fuxing Pharmaceuticals also reached 10 units.

Assuming that 10 shots are needed to treat one aplastic anemia patient, people have received treatment in Southeast Asia in just half a year!
Ten thousand people may sound like a small amount, but the final amount made Zhang Yang exclaim in surprise!
10 pieces, each priced at US$3000, with a sales amount of US$3 million!

Converted into RMB, it is as high as 21 billion!
"Brother Ren, we still have to go out to sea. The exchange rate outside is really good!" Zhang Yang couldn't help but sigh.

"Yes."

Ren Xiaomin also smiled and nodded:
"Moreover, because the country now encourages pharmaceutical exports, all drug exports are subject to zero tariffs, which means our profits are pure profits and we don't need to pay additional tariffs."

Zhang Yang nodded. In recent years, the country has indeed provided many preferential policies to encourage pharmaceutical companies to go overseas. Zero tariffs alone can save countless pharmaceutical companies a lot of taxes.

He continued to look down.

Tsingshan Pharmaceutical’s last drug is “Acofenprofovir”.

Although Qingshan Pharmaceutical has also put this drug on the shelves of JD Pharmacy and major drugstores, the main purchase volume still comes from the medical insurance special fund.

The last time "Ekofovir" was released, the medical insurance fund purchased 1000 million bottles for a total of 500 million hepatitis B patients.

This number is obviously not enough.

Therefore, this time, the purchase volume increased by 1000 million people and 2000 million bottles, with each bottle costing 500 yuan, and the total sales amount was as high as -

100 million.

Seeing this shocking number, Zhang Yang felt a little embarrassed.

However, this embarrassment only lasted for a few seconds, because he also knew that as more and more hepatitis B patients were cured, this drug would definitely not have such huge sales in the future.

He also thought about exporting this drug overseas. After all, there are still about 3 million hepatitis B patients in the world.

But apart from the 1.2 million in China, the rest are basically in India, Brazil, Egypt, Cambodia...

Especially India.

Zhang Yang couldn't help but shudder. Don't think too much. He should be thankful that India didn't come to make trouble...

While thinking, Zhang Yang continued to read.

The rest of the financial report is a series of daily expenses such as R&D expenses, production costs, and operating expenses.

These expenditures are so ostentatious in the face of sales of more than 10 billion that there is not even the interest to stay for one more second.

Finally, he saw the most critical column in the financial report, the company's total cash -

122.5 million.

Zhang Yang was stunned, his eyes seemed to be frozen at this moment, he slowly raised his head:
"So, Brother Ren, are you trying to tell me that our company now has 122.5 billion in available funds?"

Ren Xiaomin nodded excitedly and a little embarrassedly.

To be honest, neither he nor Zhang Yang had ever managed so much money.

When the first 50 billion yuan came into the medical insurance special fund, we didn’t feel anything because the money was quickly transferred out to pay for production and outsourcing costs, and not much money was left in the account.

This time, after the purchase order of 100 billion "Ekofovir" came in, Qingshan Pharmaceutical's bank balance was completely filled.

It also allowed the two of them to experience for the first time what wealth is.

After a moment, Zhang Yang rubbed his temple and couldn't help but sigh:
"Brother Ren, let me take my time..."

"You said that with so much money, what should we do?"

Ren Xiaomin was obviously also very excited:
"I thought about it when I came here. I suggested that we buy a piece of land and build our own industrial park first."

"Buying land?"

Zhang Yang thought quickly. After launching a blockbuster drug, most pharmaceutical companies in the industry would buy land to build their own industrial parks, or expand their factories and production.

At present, Zhang Yang has no idea of ​​establishing his own production base. After all, the cooperation with Lotus Pharmaceuticals is quite good.

Once you start building your own production base, not only will it require a lot of investment, but you will also need reliable people to be in charge.

Now he and Ren Xiaomin do not have enough energy to take care of this matter, so the establishment of a production base is not so urgent.

He shook his head.

"I don't think we are in a rush to buy land. We are a research and development pharmaceutical company and our land area is not that large."

"However, the factory we are in now is still rented, so we can buy it."

"We are a billion-dollar enterprise after all. If we rent even our headquarters, people will probably laugh at us if we tell them about it."

Although Ren Xiaomin was a little surprised, Zhang Yang's last sentence made him laugh.

After a moment, he nodded and said:

"You can buy this piece of land. Last time I talked to their boss, it was about 2000 million, which is a reasonable price."

"However, there are only residential buildings around here, which will be troublesome if we want to expand the factory in the future."

Zhang Yang paused for a moment, then shook his head:

"It's okay, we'll talk about it later."

"The most important thing is that this place is near the Second Ring Road, close to the city and the city, and it's very convenient for everyone to go to work."

"If we move to an industrial park outside the Third Ring Road, it will be inconvenient for people to go to work."

"Ok."

Having said this, Ren Xiaomin didn't say anything more.

At this time, Zhang Yang continued:
"Brother Ren, what do you think about taking this opportunity to increase everyone's benefits?"

"For example, pension insurance and provident fund."

Ren Xiaomin didn't expect that Zhang Yang, as the boss, would take the initiative to bring up this matter. He looked at Zhang Yang with satisfaction and said:
"I think it's okay."

"At present, although our company's pension insurance and provident fund are not the lowest compared to other pharmaceutical companies, they are not high either. If I remember correctly, it should be the second to last tier."

"Improving some welfare benefits can indeed increase everyone's sense of collective honor for the company."

Zhang Yang was also a low-level drug researcher at Beifeng Pharmaceutical. Naturally, he knew how the low-level employees felt. Isn’t the purpose of everyone going to work is to make more money?

Soon Zhang Yang called Qian Tu, the financial director who was in charge of this matter.

After briefly explaining the situation, Lao Qian replied:

"Mr. Zhang, currently domestic employee social security is divided into four levels, namely 40%, 60%, 80% and 100%."

"The higher the payment level, the more the company pays each month, and of course the higher the pension insurance the employees can get after retirement."

"Right now, our ordinary employees' social security is the second-to-last tier, which is 60%, while the project leaders of the Drug Research Center are 80%. How do you think we should adjust it?"

After a brief thought, Zhang Yang ordered:

"All ordinary employees pay 80% of the social security, and the project leaders of the research center pay 100%. After the adjustment, employees should not be required to pay the extra amount. The company will pay the extra expenses."

"Also, the provident fund contribution rate for ordinary employees is 9%, and for responsible persons it is increased to 12%, which is still the same. All the extra expenses will be paid by the company."

Qian Tu nodded repeatedly. As the financial director, he certainly knew that the company had 122.5 billion in its account.

122.5 million...

However, even so, he still admired Zhang Yang very much in his heart.

There are companies that can make money, but very few of them are able to improve the benefits of their employees as soon as they make money.

Many companies would rather make charitable donations than improve employee benefits, and at the same time want their employees to work overtime, which is simply putting the cart before the horse.

"Mr. Zhang, I'll make the arrangements now."

"it is good."

After Qian Tu left, only Zhang Yang and Ren Xiaomin were left in the office.

After chatting for a while, their attention once again fell on the large sum of money.

This time it was Ren Xiaomin who proposed:
"Zhang Yang, I think our product line is currently stable. After the successful launch of ITG synergist in the UK, we will have a large amount of income every six months. I think it would be better to invest this money in BD rather than just leaving it in the account."

"In recent years, whether it is Hengrui or foreign companies such as Pfizer and Novartis, they have been continuously increasing the number and amount of their BD transactions. This approach may be the direction of future pharmaceutical research and development."

BD transactions involve acquiring drug patents from other small pharmaceutical companies that have achieved certain results but have not yet been completed.

This time Zhang Yang did not express his opinion directly. After hesitating for a while, he shook his head slightly:

"Brother Ren, BD investment requires not only strong financial expertise, but also solid expertise in biopharmaceuticals. We don't have such talent at the moment, and it's not easy to find it."

"I have another plan."

Oh?
Ren Xiaomin's eyes focused, and he waited attentively for Zhang Yang to continue.

Zhang Yang didn't beat around the bush and said directly:
“I plan to continue to advance the development of blood disease drugs based on our existing drugs.”

"On the basis of existing drugs? Do you mean 'Qingshan Afa'?"

"That's right!"

Zhang Yang nodded:
"Before, our R&D team was small and our R&D capabilities were insufficient. I didn't have enough energy, so I didn't push this matter forward."

"After two or three years of recruitment and development, our drug research and development center has taken shape. In addition, we now have sufficient funds, so I would like to develop more drugs based on our current drugs."

"Our Qingshan Avatrombopag Tablets are the second-generation platelet-forming agent, but it will never be the last generation. There will definitely be third and fourth generations, and we can continue to upgrade."

"In addition, 'ITG human myelopoietin' can cure aplastic anemia. We can try to see if it can cure blood diseases such as leukemia or Henoch-Schonlein purpura based on it."

"So, my next idea is to invest money in this and make the best use of existing drugs to try to develop more drugs."

Ren Xiaomin nodded heavily. He completely agreed with Zhang Yang's idea.

Suddenly, he thought of the patients who left messages on Qingshan Pharmaceutical’s Weibo.

In fact, since Qingshan Pharmaceutical developed the "ITG human myelopoietin" that can cure aplastic anemia, many leukemia patients have left messages on Qingshan Pharmaceutical's Weibo.

I hope Tsingshan Pharmaceutical can start research on leukemia drugs, and I also hope that Tsingshan Pharmaceutical can develop a drug that can cure leukemia so that they can get rid of the disease as soon as possible.

If this news gets out, those leukemia patients will probably cheer.

"Zhang Yang, I agree with your idea."

“We can put the BD transaction aside for now and focus on research and development of our existing drugs first. This way, the success rate should be higher!”

Zhang Yang let out a breath and didn't continue chatting on this topic.

Suddenly, he looked up at Ren Xiaomin.

"By the way, how is Novartis in the United States?"

"Has our 'hepatocyte regeneration activator' started the first phase of clinical trials?"

……

PS: Thank you to the Annual Ring Empire for the reward of 10000 coins. Thank you, there will be more updates today.

(End of this chapter)